Anat Cohen-Dayag serves as Compugen’s President and CEO since 2010 and as a Director since 2014. Under her leadership, Compugen transformed to a therapeutic discovery and development company advancing an innovative immuno-oncology pipeline originating from the company’s computational discovery platforms. She held various R&D positions at Compugen, Mindsense Biosystems and Orgenics. Anat holds a B.Sc. in Biology from Ben-Gurion University, and an M.Sc. and a Ph.D. in life Sciences, both from the Weizmann Institute of Science.